Oxybutynin Chloride
Product Images NDC 69189-6605

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 69189-6605). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avera Mckennan Hospital, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxybutynin Xl 5 mg Tablet Label (6918966051)

Packaging label for Oxybutynin XL 5 mg tablet. The label includes manufacturer information, listing Mylan as the manufacturer and Avera McKennan Hospital in Sioux Falls, SD as the labeler. The label also displays a manufacturing lot number, hospital lot number, expiration date of 11/10/2016, and the NDC number 69189-6605-1.*

FDA Label Image

Figure 1: Mean R-oxybutynin Plasma Concentrations Following A Single Dose Of Oxybutynin Chloride Extended-release Tablets 10 mg And Oxybutynin 5 mg Administered Every 8 Hours (n = 23 For Each Treatment). (Fig1)

A line graph showing mean plasma R-oxybutynin concentration (ng/mL) over 24 hours. It compares oxybutynin chloride ER 10 mg QD and oxybutynin 5 mg TID, with values plotted at various time points along the x-axis (Time, hours) and mean concentration on the y-axis, including error bars for variability.*

FDA Label Image

Figure 2: Mean Steady State (± Sd) R-oxybutynin Plasma Concentrations Following Administration Of 5 To 20 mg Oxybutynin Chloride Extended-release Tablets Once Daily In Children Aged 5 To 15. Plot Represents All Available Data Normalized To An Equivalent Of Oxybutynin Chloride Extended-release Tablets 5 mg Once Daily. (Fig2)

A line graph showing mean R-oxybutynin plasma concentration (ng/mL) on the y-axis over time in hours on the x-axis, ranging from 0 to 24 hours. The plot includes error bars at each time point indicating variability in concentration measurements.*

FDA Label Image

Number Of Urge Incontinence Episodes Per Week (Fig3)

A figure presenting statistical data from three studies comparing mean baseline and mean change in episodes per week from baseline for Oxybutynin Chloride ER versus placebo or oxybutynin. Each study includes sample sizes, mean values with standard deviations, 95% confidence intervals, and corresponding horizontal bar graphs illustrating differences between groups.*

FDA Label Image

Oxybutynin Chloride Structural Formula (Structure)

Chemical structure of oxybutynin chloride showing its molecular components including a cyclohexyl group, phenyl ring, hydroxyl group, ester linkage, alkyne group, and diethylamino group with a hydrochloride salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.